Astellas and Teijin Pharma Extend Febuxostat Partnership To China
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Astellas will work with Teijin Pharma to market the latter's febuxostat in China and Hong Kong, expanding their partnership on the first new gout drug in 40 years
You may also be interested in...
Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded
TOKYO - Japanese firm Astellas seems content pursuing emerging market growth on its own, perhaps eschewing partnering activity like its main Japanese competitors to expand in its newest markets in the BRIC countries - Brazil, Russia, India and China
Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded
TOKYO - Japanese firm Astellas seems content pursuing emerging market growth on its own, perhaps eschewing partnering activity like its main Japanese competitors to expand in its newest markets in the BRIC countries - Brazil, Russia, India and China
Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded
Astellas outlines its growth strategy, offering ways the company plans to overcome the sales loss of U.S. patent expiries for blockbusters Prograf (tacrolimus) and Harnal (tamsulosin).